Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Rockwell Automation, Inc. today reported first quarter fiscal 2025 results. "Q1 margins and EPS came in well above our expectations this quarter, reflecting some early benefits of Rockwell's renewed ...

Think of your skin as a diary that keeps track of the days that you skipped sunscreen. Whenever you stepped out without sun ...

First Jointly Developed AI Agent Helps Customers Maximize Cisco Investments and Boosts Productivity   News Summary: Powerful Partnership: The first of several AI agents being developed by Cisco with ...

Canaccord Genuity maintained a Buy rating on Natera (NASDAQ:NTRA) shares, with a price target of $180. Trading at $169.27, the $22.35 billion market cap company enjoys strong analyst support, with a ...